𝔖 Bobbio Scriptorium

✦ LIBER ✦

Efficacy and safety of efalizumab for scalp psoriasis: Results from a prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

Book ID: 116583990
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 50 KB
Volume: 58
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2007.10.590

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of efalizumab for the treatment o

Safety of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Efficacy of efalizumab for the treatment

Efficacy of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Efficacy and safety of efalizumab in adu

Efficacy and safety of efalizumab in adults with moderate to severe plaque psoriasis and hand and foot involvement: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Assessing the Impact of Efalizumab on Na

Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial

✍ Andreas Katsambas; Ketty Peris; Gino Vena; Peter Freidmann; Gottfried Wozel; Est 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Efficacy and Safety of Efalizumab in Pat

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

✍ Torello Lotti; Sergio Chimenti; Andreas Katsambas; Jean-Paul Ortonne; Louis Dube 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

Efficacy and safety of efalizumab in pat

Efficacy and safety of efalizumab in patients with chronic moderate to severe plaque psoriasis: Results from a postapproval phase IIIb/IV study (control II)

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB